Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 27 peer-reviewed journal articles Updated
Hematology

Living with MZL: Long-Term Monitoring and Survivorship

At a Glance

Marginal Zone Lymphoma (MZL) is typically a slow-growing condition managed through long-term monitoring rather than an immediate cure. Survivorship involves regular clinical exams, managing immune system side effects, avoiding unnecessary scans, and watching for new "B symptoms."

Living with Marginal Zone Lymphoma (MZL) is often less about finding a “cure” and more about managing a chronic condition. Because MZL is typically indolent (slow-growing), you may spend years or even decades in a “watch and wait” phase or in remission after treatment [1][2]. While the idea of living with a “chronic cancer” can be daunting, the goal of survivorship is to ensure the disease stays in the background of a full, active life [3][4].

The Rhythm of Monitoring

Whether you are in watch and wait or in remission, your medical team will establish a regular monitoring schedule. This is not “doing nothing”; it is a proactive strategy to catch changes early [5][6].

  • Clinical Exams: In the beginning, you may see your hematologist every 3 to 6 months for a physical exam and blood work [7]. Over time, if your disease remains stable, these visits may move to once or twice a year [8].
  • Blood Work: Doctors look for changes in your LDH levels, hemoglobin, and white blood cell counts, which can provide early clues about disease activity [9][10].
  • The Truth About Scans: If your doctor does order a scan based on new symptoms or lab changes, it is a valid and safe investigative tool to see what is happening inside your body. But for patients without symptoms, routine “surveillance” scans (CT or PET) are often not recommended [5][11]. Scans carry risks of radiation exposure and can lead to “false positives” (findings that look like cancer but aren’t), causing unnecessary anxiety and biopsies [12]. Most doctors rely on how you feel and your physical exam to decide if a scan is truly needed [8].

Managing “Scanxiety” and Uncertainty

The psychological toll of living with MZL—especially the anxiety that builds before a check-up, known as “scanxiety”—is real and valid [13][14].

  • Mind-Body Support: Evidence shows that yoga, Tai chi, and meditation can significantly reduce cancer-related anxiety and fatigue [15][16].
  • Counseling: Cognitive Behavioral Therapy (CBT) has been shown to help patients manage the “anxious preoccupation” that can come with a chronic diagnosis [17][18].
  • Active Living: Regular aerobic and resistance exercise (like walking or light weightlifting) is one of the most effective ways to improve both your mood and your long-term energy levels [3].

Long-Term Health Considerations

Treatments like rituximab are highly effective, but they can have long-lasting effects on your immune system that require monitoring [19].

  • Hypogammaglobulinemia: This is a condition where your antibody levels (specifically IgG) drop because the treatment has depleted your B-cells [19][20]. This can lead to more frequent infections, such as sinus or lung infections [21]. Your doctor should monitor your IgG levels regularly; if they become too low, you may need immunoglobulin replacement therapy [22][23].
  • Vaccination Timing: Because rituximab clears out the cells that make antibodies, it is critical to update your essential vaccines (like flu, pneumonia, or COVID) before you start treatment if possible. Once you receive rituximab, vaccines may not work as well, and guidelines generally suggest waiting 6 to 12 months after your last dose for the best response [24][25].
  • Second Cancers: Like all lymphoma survivors, you should stay up to date on standard cancer screenings (such as colonoscopies and skin checks), as there is a slightly higher risk of developing a second, unrelated cancer later in life [26].

When to Call Your Doctor

Between scheduled visits, you should contact your care team if you notice any “red flag” symptoms that could suggest the disease is becoming more active:

  • New or growing lumps (swollen lymph nodes).
  • “B symptoms”: unexplained fevers (typically a temperature of 100.4°F or higher), drenching night sweats, or losing more than 10% of your body weight without trying [27].
  • Severe fatigue that doesn’t go away with rest.
  • Persistent pain in your abdomen or chest.

Living with MZL means being a vigilant but empowered observer of your own health. By staying active and staying connected to your care team, you can manage the challenges of this diagnosis while focusing on what matters most to you.

Common questions in this guide

How often will I need check-ups during the watch and wait phase for MZL?
In the beginning, you will typically see your hematologist every 3 to 6 months for a physical exam and blood work. If your disease remains stable over time, these visits may be reduced to once or twice a year.
Do I need routine CT or PET scans to monitor my MZL?
For patients without symptoms, routine surveillance scans are usually not recommended due to radiation exposure and the risk of false positives. Doctors typically rely on your physical exam, blood work, and how you feel to decide if a scan is necessary.
What are the "B symptoms" of lymphoma that I should watch for?
B symptoms include unexplained fevers of 100.4°F or higher, drenching night sweats, and losing more than 10% of your body weight without trying. You should contact your doctor immediately if you experience any of these signs.
Why do I get more frequent infections after MZL treatment?
Treatments like rituximab can lower your antibody levels, causing a condition called hypogammaglobulinemia. This makes you more susceptible to sinus, lung, and other infections, which may require immunoglobulin replacement therapy if levels drop too low.
When should I get my vaccines if I need MZL treatment?
It is critical to update essential vaccines, such as those for flu, pneumonia, or COVID-19, before starting treatment like rituximab. After treatment, you generally need to wait 6 to 12 months for vaccines to be effective again.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How often should I have my blood work and physical exams performed while in 'watch and wait' or remission?
  2. 2.Do you recommend routine surveillance scans (CT or PET) for me, or will we rely primarily on my symptoms and physical exams?
  3. 3.When was my last immunoglobulin (IgG) level checked, and do my results show any signs of rituximab-induced hypogammaglobulinemia?
  4. 4.What is the best timing for my next flu, COVID-19, or shingles vaccination relative to my last (or next) treatment?
  5. 5.What specific symptoms or changes should I watch for that would indicate the lymphoma is becoming more active?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (27)
  1. 1

    Epidemiology of Marginal Zone Lymphoma.

    Cerhan JR, Habermann TM

    Annals of lymphoma 2021; (5()) doi:10.21037/aol-20-28.

    PMID: 33829216
  2. 2

    Results of Upfront Therapy for Marginal Zone Lymphoma.

    Ortega JL, Cabanillas F, Rivera N, et al.

    Clinical lymphoma, myeloma & leukemia 2017; (17(12)):879-883 doi:10.1016/j.clml.2017.09.014.

    PMID: 29042174
  3. 3

    Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable.

    Campbell KL, Winters-Stone KM, Wiskemann J, et al.

    Medicine and science in sports and exercise 2019; (51(11)):2375-2390 doi:10.1249/MSS.0000000000002116.

    PMID: 31626055
  4. 4

    Prognostic outcome of extranodal marginal zone B-cell lymphoma: a nationwide cohort.

    Nam SY, Jo J

    Scientific reports 2025; doi:10.1038/s41598-025-32259-5.

    PMID: 41402369
  5. 5

    Splenic marginal zone lymphoma in Sweden 2000-2020: Increasing rituximab use and better survival in the elderly.

    Junlén HR, Sonnevi K, Lindén O, et al.

    EJHaem 2023; (4(3)):647-655 doi:10.1002/jha2.696.

    PMID: 37601869
  6. 6

    Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma.

    Cheah CY, Opat S, Trotman J, Marlton P

    Internal medicine journal 2019; (49(9)):1070-1080 doi:10.1111/imj.14268.

    PMID: 30816618
  7. 7

    Management of Marginal Zone Lymphoma: A Canadian Perspective.

    Peters A, Keating MM, Nikonova A, et al.

    Current oncology (Toronto, Ont.) 2023; (30(2)):1745-1759 doi:10.3390/curroncol30020135.

    PMID: 36826096
  8. 8

    Advances in the Pathogenesis, Diagnosis, Treatment, and Prognosis of Marginal Zone Lymphoma.

    Zhang Q, Yan W, Li H, Peng H

    Current treatment options in oncology 2025; (26(2)):142-155 doi:10.1007/s11864-025-01293-w.

    PMID: 39891871
  9. 9

    Marginal B-cell lymphoma: A 10-year retrospective study at national institute of hematology and blood transfusion, Vietnam.

    Vu BD, Nguyen HQ, Le CQ, et al.

    SAGE open medicine 2025; (13()):20503121251334508 doi:10.1177/20503121251334508.

    PMID: 40297783
  10. 10

    Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment.

    Arcaini L, Bommier C, Alderuccio JP, et al.

    EClinicalMedicine 2024; (72()):102592 doi:10.1016/j.eclinm.2024.102592.

    PMID: 38633575
  11. 11

    Role of imaging in low-grade cutaneous B-cell lymphoma presenting in the skin.

    Kheterpal MK, Dai J, Geller S, et al.

    Journal of the American Academy of Dermatology 2019; (81(4)):970-976 doi:10.1016/j.jaad.2019.01.037.

    PMID: 30703460
  12. 12

    FDG PET/CT as a diagnostic and prognostic tool for the evaluation of marginal zone lymphoma.

    Vaxman I, Bernstine H, Kleinstern G, et al.

    Hematological oncology 2019; (37(2)):168-175 doi:10.1002/hon.2578.

    PMID: 30734341
  13. 13

    Perceived diagnostic delay and cancer-related distress: a cross-sectional study of patients with colorectal cancer.

    Miles A, McClements PL, Steele RJ, et al.

    Psycho-oncology 2017; (26(1)):29-36 doi:10.1002/pon.4093.

    PMID: 26868950
  14. 14

    Greater financial toxicity relates to greater distress and worse quality of life among breast and gynecologic cancer survivors.

    Benedict C, Fisher S, Schapira L, et al.

    Psycho-oncology 2022; (31(1)):9-20 doi:10.1002/pon.5763.

    PMID: 34224603
  15. 15

    A pilot randomized controlled trial of a yoga program for alleviating cancer-related fatigue and psychological distress in women with gynecological cancer.

    Ma X, Shang M, Wong CL, et al.

    European journal of oncology nursing : the official journal of European Oncology Nursing Society 2025; (74()):102731 doi:10.1016/j.ejon.2024.102731.

    PMID: 39561472
  16. 16

    Mind-body practices for cancer-related symptoms management: an overview of systematic reviews including one hundred twenty-nine meta-analyses.

    Casuso-Holgado MJ, Heredia-Rizo AM, Gonzalez-Garcia P, et al.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2022; (30(12)):10335-10357 doi:10.1007/s00520-022-07426-3.

    PMID: 36322248
  17. 17

    Evaluating the efficacy of a self-guided Web-based CBT intervention for reducing cancer-distress: a randomised controlled trial.

    Beatty L, Koczwara B, Wade T

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2016; (24(3)):1043-51 doi:10.1007/s00520-015-2867-6.

    PMID: 26248651
  18. 18

    Anxiety and Depression in Cancer Survivors.

    Yi JC, Syrjala KL

    The Medical clinics of North America 2017; (101(6)):1099-1113 doi:10.1016/j.mcna.2017.06.005.

    PMID: 28992857
  19. 19

    Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab.

    Athni TS, Barmettler S

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2023; (130(6)):699-712 doi:10.1016/j.anai.2023.01.018.

    PMID: 36706910
  20. 20

    Secondary Hypogammaglobulinemia After Rituximab for Neuromyelitis Optica: A Case Report.

    Farhat L, Dara J, Duberstein S, De A

    Drug safety - case reports 2018; (5(1)):22 doi:10.1007/s40800-018-0087-y.

    PMID: 29752554
  21. 21

    Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction: a multicentre study.

    Podestà MA, Mescia F, Ricchiuto A, et al.

    Rheumatology (Oxford, England) 2023; (62(8)):2850-2854 doi:10.1093/rheumatology/keac716.

    PMID: 36562566
  22. 22

    Evidence- and Consensus-Based Recommendations for the Screening, Diagnosis, and Management of Secondary Hypogammaglobulinemia in Patients With Systemic Autoimmune Rheumatic Diseases by the Taiwan College of Rheumatology Experts.

    Tsao YP, Chen HH, Hsieh TY, et al.

    International journal of rheumatic diseases 2025; (28(6)):e70310 doi:10.1111/1756-185X.70310.

    PMID: 40522036
  23. 23

    Infection screening prior to Ocrelizumb initiation in patients with Multiple Sclerosis (MS): Concise clinical recommendation based on a modified Delphi consensus on behalf of the Iranian MS -infectious disease group.

    Paybast S, Abutorabi-Zarchi M, Ashtari F, et al.

    Multiple sclerosis and related disorders 2026; (105()):106824 doi:10.1016/j.msard.2025.106824.

    PMID: 41265015
  24. 24

    The optimal interval before receiving SARS-COV-2 vaccination for patients who have received Anti-CD 20 monoclonal antibodies.

    Liu K, Li J, Xu G

    Virulence 2022; (13(1)):2012-2021 doi:10.1080/21505594.2022.2146380.

    PMID: 36372876
  25. 25

    Vaccinations in hematological patients in the era of target therapies: Lesson learnt from SARS-CoV-2.

    Fattizzo B, Rampi N, Barcellini W

    Blood reviews 2023; (60()):101077 doi:10.1016/j.blre.2023.101077.

    PMID: 37029066
  26. 26

    Baseline immunoglobulin G and immune function in non-Hodgkin lymphoma: a retrospective analysis.

    Brazel D, Grant C, Cabal A, et al.

    Frontiers in immunology 2024; (15()):1334899 doi:10.3389/fimmu.2024.1334899.

    PMID: 38745669
  27. 27

    CD5 expression in marginal zone lymphoma predicts differential response to rituximab or bendamustine/rituximab.

    Hsu A, Kurt H, Zayac AS, Olszewski AJ

    Leukemia & lymphoma 2022; (63(1)):31-42 doi:10.1080/10428194.2021.1973670.

    PMID: 34467833

This page provides educational information about living with and monitoring Marginal Zone Lymphoma (MZL). It is not a substitute for professional medical advice from your hematologist or oncologist.

Get notified when new evidence is published on Marginal zone lymphoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.